Recruiting
Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma
Registered drugNo placebo
Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma
Registered drugNo placebo
- Disease:Anaplastic large cell lymphoma T- and null-cell typesNeuroblastoma+2
- Substances:CrizotinibTemsirolimus
Countries:
Denmark
Denmark- Participants:0–17 years · 18–64 years
- Substances:Crizotinib



